通天酒業(00389.HK)擬與瀘州老窖新酒業合作共同研發新產品及擴大產品類別
格隆匯5月29日丨通天酒業(00389.HK)公吿,於2024年5月29日,公司與瀘州老窖新酒業有限公司("瀘州老窖新酒業")簽訂策略合作協議,瀘州老窖新酒業是瀘州老窖股份有限公司的間接全資擁有子公司,瀘州老窖股份有限公司是在深圳證劵交易所掛牌,(股票代號:000568)。
瀘州老窖新酒業成立於四川省,公司主營精釀啤酒、輕酒飲、中式果釀及蒸餾酒和酒類衍生品,共四類產品。集團擬通過與瀘州老窖新酒業的策略合作,將共同研發新產品,擴大產品類別,及擴闊分銷渠道及銷售推廣。董事會認為簽訂此策略合作協議將為公司帶來商機。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.